We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
+38.63%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$146M
AUM Growth
–
Cap. Flow
+$125M
Cap. Flow %
85.57%
Top 10 Hldgs %
77.22%
Holding
23
New
22
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
UAM
Universal American Corp
UAM
+$26.1M
2
OREX
Orexigen Therapeutics, Inc.
OREX
+$20.2M
3
LRMR icon
Larimar Therapeutics
LRMR
+$10.7M
4
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$5.98M
5
SCYX icon
SCYNEXIS
SCYX
+$5.86M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 74.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UAM
1
DELISTED
Universal American Corp
UAM
$27.8M 19.06%
+3,000,000
New +$26.1M
OREX
2
DELISTED
Orexigen Therapeutics, Inc.
OREX
$24.3M 16.67%
+401,767
New +$20.2M
LRMR icon
3
Larimar Therapeutics
LRMR
$416M
$15.4M 10.56%
+41,681
New +$10.7M
ASPX
4
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$9.02M 6.17%
+171,824
New +$5.05M
ALDR
5
DELISTED
Alder Biopharmaceuticals
ALDR
$7.13M 4.88%
+245,000
New +$4.4M
SCYX icon
6
SCYNEXIS
SCYX
$37M
$6.62M 4.53%
+8,287
New +$5.86M
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
$6.42M 4.4%
+220,067
New +$5.58M
QTNT
8
DELISTED
Quotient Limited Ordinary Shares
QTNT
$5.9M 4.04%
+8,191
New +$3.89M
SAGE
9
DELISTED
Sage Therapeutics
SAGE
$5.29M 3.62%
+144,569
New +$5.39M
JUNO
10
DELISTED
Juno Therapeutics, Inc.
JUNO
$4.78M 3.27%
+91,575
New +$4.1M
BDSI
11
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$4.73M 3.24%
+393,683
New +$5.98M
TTOO
12
DELISTED
T2 Biosystems, Inc
TTOO
$4.39M 3.01%
+46
New +$3.79M
EPZM
13
DELISTED
Epizyme, Inc
EPZM
$3.81M 2.61%
+201,806
New +$4.71M
PRQR icon
14
ProQR Therapeutics
PRQR
$243M
$3.75M 2.57%
+173,067
New +$2.63M
ANAC
15
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$3.45M 2.36%
+106,849
New +$3.21M
AGRX
16
DELISTED
Agile Therapeutics
AGRX
$3.28M 2.25%
+267
New +$3.39M
BLCM
17
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.42M 1.66%
+10,500
New +$2.25M
BDSI
18
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.04M 1.4%
+170,000
New +$2.58M
RXDX
19
DELISTED
Ignyta, Inc.
RXDX
$1.88M 1.29%
+275,000
New +$1.87M
OREX
20
CALL
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.52M 1.04%
+25,150
New +$1.26M
BDSI
21
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.2M 0.82%
+100,000
New +$1.52M
OREX
22
PUT
DELISTED
Orexigen Therapeutics, Inc.
OREX
$606K 0.42%
+10,000
New +$502K
SINT icon
23
SiNtx Technologies
SINT
$8.9M
– –
0
– –

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q4 2014 Portfolio in Review

Q4 2014 is the first quarter with a 13F filing on record for Foresite Capital Management II, which disclosed 23 positions worth $146M. Its ten largest holdings account for 77% of the portfolio.

Its largest position is Universal American Corp: 3,000,000 shares worth $27.8M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets.

  • Foresite Capital Management II's largest Q4 2014 buy was Universal American Corp: 3,000,000 shares worth $27.8M.
  • Foresite Capital Management II's ten largest holdings make up 77% of its $146M portfolio in Q4 2014.
  • Foresite Capital Management II disclosed 23 positions in Q4 2014, its first 13F filing on record.

Based on Foresite Capital Management II's 13F filing for Q4 2014, filed 11 Feb 2015.